Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in Start Up

Executive Summary

ImVisioN GMBH's focus is allergy immunotherapy, and it is using its platform technologies to create a pipeline of treatments for major allergies. ILIT, ImVisioN's delivery technology, allows administration of the allergen directly into the lymph nodes, which contain high concentrations of antigen-presenting cells. Its MAT technology is designed to maximize the immune protective response from T helper cell type 1 and minimize the Th2-mediated inflammatory responses.

Related Content

Start-Up Previews (6/07)
Start-Up Previews (6/07)


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts